The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Presentation
Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C
Matthew D. Galsky, Vadim S. Koshkin, Matthew T. Campbell, Alexandra Drakaki, Isaac Bowman, April A.N. Rose, Jason R. Brown, Jeanny B. Aragon-Ching, Saikrishna Gadde, Amir Harandi, Jonathan E. Rosenberg, Nobuaki Matsubara, Kevin M. Sokolowski, Mari Ichimaru, Stephanie Chan, Sonia Franco, Thomas B. Powles
Disitamab vedotin | PF-08046051 | September 15, 2024 | ESMO 2024
C5731002 | NCT04879329
Poster
Phase 2 study of disitamab vedotin in patients with HER2-expressing non-small cell lung cancer (DV‑005; trial in progress)
Jonathan W. Riess, Bhavana Pothuri, Nashat Gabrail, Vincent Castonguay, Rachel E. Sanborn, Sujith Kalmadi, Xuemei Li, Miao Yang, Ecaterina Elena Dumbrava, Joyce F. Liu
Disitamab vedotin | PF-08046051 | September 8, 2024 | WCLC 2024
C5731005 | NCT06003231